Immunovant's IMVT-1402 Hits Primary Endpoint in D2T RA With 92.5% ACR20 Response
IMVT sits 31% above its 52-week low of $21.43 on elevated volume (1.9× avg).
Summary
Immunovant's IMVT-1402 600 mg met the primary endpoint in a potentially registrational trial in difficult-to-treat rheumatoid arthritis, with a 92.5% ACR20 response at Week 28 versus 75.6% for placebo. The 300 mg arm showed 75.0% ACR20 and no difference versus placebo, so the efficacy signal is specific to the 600 mg dose. The company plans FDA discussions on the registrational path for D2T RA later this year. Cash and equivalents stood at $722.3M at September 30, which management says funds the current operating plan through a potential Graves' disease commercial launch. On the negative side, Immunovant does not expect to advance IMVT-1402 further in SjD beyond the fully enrolled Phase 2 trial, narrowing that indication. Topline Graves' disease and myasthenia gravis trial data are expected in 2027.
At the time of this announcement, IMVT was trading at $28.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.3B. The 52-week trading range was $21.43 to $45.42. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.